<DOC>
	<DOCNO>NCT00113971</DOCNO>
	<brief_summary>The goal study evaluate epratuzumab process body ( pharmacokinetics ) whether 2 dose level epratuzumab safe effective patient SLE .</brief_summary>
	<brief_title>Pharmacokinetics Study Epratuzumab Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>This study plan provide information body process epratuzumab epratuzumab affect body epratuzumab give weekly 4 week row one 2 different dose level . Additional information obtain related natural variability disease activity SLE patient .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Has SLE American College Rheumatology revise criterion ( meet &gt; /= 4 criterion ) Has SLE least 6 month prior study entry Has least one elevate autoantibody level study entry Has moderately active SLE disease study entry body/organ system ( Full criterion present due length consideration . The protocol consult regard complete list entry criterion . ) Exclusion criterion : Active Severe Lupus define BILAG Index Level A body system organ Allergy human antibody Murine Prior therapy antiB cell antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>study epratuzumab systemic lupus erythematosus</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>SLE</keyword>
</DOC>